Vantage Investment Partners LLC Has $49.93 Million Holdings in Novo Nordisk A/S (NYSE:NVO)

Vantage Investment Partners LLC lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 35.4% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 580,417 shares of the company’s stock after purchasing an additional 151,620 shares during the period. Novo Nordisk A/S comprises approximately 4.4% of Vantage Investment Partners LLC’s holdings, making the stock its 4th biggest position. Vantage Investment Partners LLC’s holdings in Novo Nordisk A/S were worth $49,927,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Strategic Investment Solutions Inc. IL bought a new position in Novo Nordisk A/S in the second quarter worth approximately $25,000. Daiwa Securities Group Inc. bought a new position in Novo Nordisk A/S in the 3rd quarter worth $28,000. Capital Performance Advisors LLP bought a new position in Novo Nordisk A/S in the 3rd quarter worth $42,000. Albion Financial Group UT lifted its position in Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after purchasing an additional 278 shares in the last quarter. Finally, Sound Income Strategies LLC grew its holdings in Novo Nordisk A/S by 82.1% during the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock valued at $46,000 after purchasing an additional 243 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on NVO. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BMO Capital Markets decreased their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S currently has an average rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Stock Performance

NVO opened at $87.45 on Tuesday. The stock has a market capitalization of $392.43 billion, a price-to-earnings ratio of 28.30, a PEG ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The company has a fifty day moving average of $95.35 and a 200 day moving average of $114.80.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.